Official reprint from UpToDate®
www.uptodate.com ©2018 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Intrauterine contraceptive device: Insertion and removal

Deborah A Bartz, MD, MPH
Katherine D Pocius, MD, MPH
Section Editor
Courtney A Schreiber, MD, MPH
Deputy Editor
Kristen Eckler, MD, FACOG


Intrauterine contraception is highly effective, very safe, and generally well tolerated by most women. Intrauterine device (IUD) insertion and removal are usually relatively simple procedures that can be performed in the office setting by trained providers. The technical skills required for device insertion and removal can be obtained through proctored hands-on training in the clinical setting and/or may be provided by the manufacturers of these devices. This review is not intended as a substitute for hands-on clinical training.

This topic will address technical issues regarding the insertion and removal procedures for the copper-releasing and progestin-containing IUDs. Other aspects of intrauterine contraception, including detailed review of candidates, device selection, and management of complications, as well as selection of contraception in general and specifically postpartum, are reviewed separately:

(See "Intrauterine contraception: Devices, candidates, and selection".)

(See "Intrauterine contraception: Management of side effects and complications".)

(See "Contraceptive counseling and selection".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Dec 2017. | This topic last updated: Dec 06, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2018 UpToDate, Inc.
  1. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
  2. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 2011; 118:184.
  3. Dehlendorf C, Henderson JT, Vittinghoff E, et al. Association of the quality of interpersonal care during family planning counseling with contraceptive use. Am J Obstet Gynecol 2016; 215:78.e1.
  4. Whiteman MK, Tyler CP, Folger SG, et al. When can a woman have an intrauterine device inserted? A systematic review. Contraception 2013; 87:666.
  5. Bergin A, Tristan S, Terplan M, et al. A missed opportunity for care: two-visit IUD insertion protocols inhibit placement. Contraception 2012; 86:694.
  6. Centers for Disease Control and Prevention. STI and HIV Screening Recommendations. April 2017. https://www.cdc.gov/std/prevention/screeningreccs.htm (Accessed on September 12, 2017).
  7. Torrone E, Papp J, Weinstock H, Centers for Disease Control and Prevention (CDC). Prevalence of Chlamydia trachomatis genital infection among persons aged 14-39 years--United States, 2007-2012. MMWR Morb Mortal Wkly Rep 2014; 63:834.
  8. Muzny CA, Harbison HS, Austin EL, et al. Sexually Transmitted Infection Risk among Women Is Not Fully Explained by Partner Numbers. South Med J 2017; 110:161.
  9. Caddy S, Yudin MH, Hakim J, et al. Best practices to minimize risk of infection with intrauterine device insertion. J Obstet Gynaecol Can 2014; 36:266.
  10. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
  11. Pham AT, Kives S, Merovitz L, et al. Screening for bacterial vaginosis at the time of intrauterine contraceptive device insertion: is there a role? J Obstet Gynaecol Can 2012; 34:179.
  12. Ferraz do Lago R, Simões JA, Bahamondes L, et al. Follow-up of users of intrauterine device with and without bacterial vaginosis and other cervicovaginal infections. Contraception 2003; 68:105.
  13. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
  14. Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:887.
  15. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.
  16. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev 2001; :CD001327.
  17. ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 104: Antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009; 113:1180. Reaffirmed 2016.
  18. Durack DT. Prevention of infective endocarditis. N Engl J Med 1995; 332:38.
  19. Ireland LD, Allen RH. Pain Management for Gynecologic Procedures in the Office. Obstet Gynecol Surv 2016; 71:89.
  20. Lopez LM, Bernholc A, Zeng Y, et al. Interventions for pain with intrauterine device insertion. Cochrane Database Syst Rev 2015; :CD007373.
  21. Akers AY, Steinway C, Sonalkar S, et al. Reducing Pain During Intrauterine Device Insertion: A Randomized Controlled Trial in Adolescents and Young Women. Obstet Gynecol 2017; 130:795.
  22. Crawford M, Davy S, Book N, et al. Oral Ketorolac for Pain Relief During Intrauterine Device Insertion: A Double-Blinded Randomized Controlled Trial. J Obstet Gynaecol Can 2017; 39:1143.
  23. Ngo LL, Braaten KP, Eichen E, et al. Naproxen Sodium for Pain Control With Intrauterine Device Insertion: A Randomized Controlled Trial. Obstet Gynecol 2016; 128:1306.
  24. Abbas AM, Abdellah MS, Khalaf M, et al. Effect of cervical lidocaine-prilocaine cream on pain perception during copper T380A intrauterine device insertion among parous women: A randomized double-blind controlled trial. Contraception 2017; 95:251.
  25. Karasu Y, Cömert DK, Karadağ B, Ergün Y. Lidocaine for pain control during intrauterine device insertion. J Obstet Gynaecol Res 2017; 43:1061.
  26. Matthews LR, OʼDwyer L, OʼNeill E. Intrauterine Device Insertion Failure After Misoprostol Administration: A Systematic Review. Obstet Gynecol 2016; 128:1084.
  27. Singh RH, Thaxton L, Carr S, et al. A randomized controlled trial of nitrous oxide for intrauterine device insertion in nulliparous women. Int J Gynaecol Obstet 2016; 135:145.
  28. American College of Obstetricians and Gynecologists Women's Health Care Physicians, Committee on Gynecologic Practice. Committee Opinion No. 571: Solutions for surgical preparation of the vagina. Obstet Gynecol 2013; 122:718. Reaffirmed 2018.
  29. Farmer M, Webb A. Intrauterine device insertion-related complications: Can they be predicted? J Fam Plann Reprod Health Care 2003; 29:227.
  30. Zhang J. Factors associated with copper T IUD removal for bleeding/pain: a multivariate analysis. Contraception 1993; 48:13.
  31. Culwell KR, Curtis KM. Use of contraceptive methods by women with current venous thrombosis on anticoagulant therapy: a systematic review. Contraception 2009; 80:337.
  32. Mirena package insert. US FDA approved product information; Whippany, NJ: Bayer Healthcare; June, 2017. https://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf (Accessed on June 20, 2017).
  33. Liletta intrauterine contraceptive system. US FDA approved product information; Irvine, CA: Allergan USA; 2016. https://www.allergan.com/assets/pdf/lilettashi_pi (Accessed on June 20, 2017).
  34. Kyleena (levonorgestrel-releasing intrauterine system). US FDA approved product information; Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2016. http://labeling.bayerhealthcare.com/html/products/pi/Kyleena_PI.pdf (Accessed on June 20, 2017).
  35. Skyla [package insert].Whippany, NJ: Bayer HealthCare Pharmaceuticals; 2017. http://labeling.bayerhealthcare.com/html/products/pi/Skyla_PI.pdf (Accessed on November 10, 2017).
  36. Paragard T380A Intrauterine Copper Contraceptive. US FDA approved product information; North Wales, PA: Teva Pharmaceuticals USA; 2014. http://paragard.com/pdf/PARAGARD-PI.pdf (Accessed on June 20, 2017).
  37. Liletta IUS with inserter. US FDA approved product information; Parsippany, NJ: Actavis Pharma Inc; 2015. https://www.allergan.com/assets/pdf/liletta_pi (Accessed on June 20, 2017).
  38. Mirena IUD insertion and removal video. http://hcp.mirena-us.com/mirena-insertion-removal-video/ (Accessed on September 12, 2017).
  39. Skyla insertion and removal video. http://hcp.skyla-us.com/insertion-and-removal/ (Accessed on September 12, 2017).
  40. Liletta Resources: placement https://www.lilettahcp.com/resources/placement (Accessed on September 12, 2017).
  41. Christenson K, Lerma K, Shaw KA, Blumenthal PD. Assessment of a simplified insertion technique for intrauterine devices. Int J Gynaecol Obstet 2016; 134:29.
  42. Paragard package insert. North Wales, PA: Teva Women's Health; 9/2014.
  43. Sääv I, Aronsson A, Marions L, et al. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: A randomized controlled trial. Hum Reprod 2007; 22:2647.
  44. Li YT, Kuo TC, Kuan LC, Chu YC. Cervical softening with vaginal misoprostol before intrauterine device insertion. Int J Gynaecol Obstet 2005; 89:67.
  45. Vickery Z, Madden T. Difficult intrauterine contraception insertion in a nulligravid patient. Obstet Gynecol 2011; 117:391.
  46. Meckstroth KR, Whitaker AK, Bertisch S, et al. Misoprostol administered by epithelial routes: Drug absorption and uterine response. Obstet Gynecol 2006; 108:582.
  47. Bednarek PH, Creinin MD, Reeves MF, et al. Immediate versus delayed IUD insertion after uterine aspiration. N Engl J Med 2011; 364:2208.
  48. Goldthwaite LM, Shaw KA. Immediate postpartum provision of long-acting reversible contraception. Curr Opin Obstet Gynecol 2015; 27:460.
  49. Pocius KD, Maurer R, Fortin J, et al. Early serum human chorionic gonadotropin (hCG) trends after medication abortion. Contraception 2015; 91:503.
  50. Pocius KD, Bartz D, Maurer R, et al. Serum human chorionic gonadotropin (hCG) trend within the first few days after medical abortion: a prospective study. Contraception 2017; 95:263.
  51. Dayananda I, Maurer R, Fortin J, Goldberg AB. Medical abortion follow-up with serum human chorionic gonadotropin compared with ultrasonography: a randomized controlled trial. Obstet Gynecol 2013; 121:607.
  52. Intrauterine devices. Their role in family planning care. WHO Offset Publ 1983; :1.
  53. Cohen R, Sheeder J, Arango N, et al. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices. Contraception 2016; 93:178.
  54. Woo I, Seifert S, Hendricks D, et al. Six-month and 1-year continuation rates following postpartum insertion of implants and intrauterine devices. Contraception 2015; 92:532.
  55. Lerma K, Singh S, Bhamrah R, Blumenthal PD. Does the time between delivery and insertion of the IUD have clinical significance in the provision of postpartum IUDS? Contraception 2017; 96:267.
  56. Lopez LM, Bernholc A, Hubacher D, et al. Immediate postpartum insertion of intrauterine device for contraception. Cochrane Database Syst Rev 2015; :CD003036.
  57. Lester F, Kakaire O, Byamugisha J, et al. Intracesarean insertion of the Copper T380A versus 6 weeks postcesarean: a randomized clinical trial. Contraception 2015; 91:198.
  58. Baldwin MK, Edelman AB, Lim JY, et al. Intrauterine device placement at 3 versus 6 weeks postpartum: a randomized trial. Contraception 2016; 93:356.
  59. Zerden ML, Stuart GS, Charm S, et al. Two-week postpartum intrauterine contraception insertion: a study of feasibility, patient acceptability and short-term outcomes. Contraception 2017; 95:65.
  60. Glazener CM. Sexual function after childbirth: women's experiences, persistent morbidity and lack of professional recognition. Br J Obstet Gynaecol 1997; 104:330.
  61. Elliott SA, Watson JP. Sex during pregnancy and the first postnatal year. J Psychosom Res 1985; 29:541.
  62. Connolly A, Thorp J, Pahel L. Effects of pregnancy and childbirth on postpartum sexual function: a longitudinal prospective study. Int Urogynecol J Pelvic Floor Dysfunct 2005; 16:263.